Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives $62.67 Average Price Target from Analysts

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) have been assigned an average rating of “Buy” from the six ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $63.25.

SUPN has been the subject of a number of recent analyst reports. Zacks Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, September 17th. TD Cowen raised their price objective on Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Piper Sandler raised Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $40.00 to $65.00 in a research report on Thursday, October 9th. Wall Street Zen downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, October 8th.

Supernus Pharmaceuticals Stock Up 1.5%

Shares of Supernus Pharmaceuticals stock opened at $56.50 on Tuesday. The business’s fifty day simple moving average is $47.81 and its 200-day simple moving average is $38.61. The firm has a market cap of $3.17 billion, a PE ratio of 49.13 and a beta of 0.78. Supernus Pharmaceuticals has a 52 week low of $29.16 and a 52 week high of $57.65.

Insider Buying and Selling

In related news, CFO Timothy C. Dec sold 11,780 shares of the firm’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $44.49, for a total transaction of $524,092.20. Following the completion of the transaction, the chief financial officer directly owned 1,246 shares in the company, valued at $55,434.54. This trade represents a 90.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Frank Mottola sold 5,000 shares of the firm’s stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $45.87, for a total value of $229,350.00. Following the transaction, the senior vice president owned 15,496 shares of the company’s stock, valued at $710,801.52. This trade represents a 24.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 362,741 shares of company stock valued at $16,390,592. 8.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Armistice Capital LLC boosted its holdings in Supernus Pharmaceuticals by 7.4% during the 1st quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company’s stock valued at $170,169,000 after acquiring an additional 360,000 shares during the period. State Street Corp boosted its holdings in Supernus Pharmaceuticals by 2.9% during the 2nd quarter. State Street Corp now owns 2,208,560 shares of the specialty pharmaceutical company’s stock valued at $69,614,000 after acquiring an additional 63,210 shares during the period. Geode Capital Management LLC boosted its holdings in Supernus Pharmaceuticals by 5.5% during the 2nd quarter. Geode Capital Management LLC now owns 1,399,610 shares of the specialty pharmaceutical company’s stock valued at $44,121,000 after acquiring an additional 72,991 shares during the period. GW&K Investment Management LLC raised its position in Supernus Pharmaceuticals by 14.6% in the 1st quarter. GW&K Investment Management LLC now owns 1,382,441 shares of the specialty pharmaceutical company’s stock valued at $45,275,000 after purchasing an additional 176,091 shares in the last quarter. Finally, Sofinnova Investments Inc. raised its position in Supernus Pharmaceuticals by 53.5% in the 2nd quarter. Sofinnova Investments Inc. now owns 799,253 shares of the specialty pharmaceutical company’s stock valued at $25,192,000 after purchasing an additional 278,575 shares in the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.